Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.44
- Piotroski Score 4.00
- Grade Buy
- Symbol (XFOR)
- Company X4 Pharmaceuticals, Inc.
- Price $0.64
- Changes Percentage (1.73%)
- Change $0.01
- Day Low $0.62
- Day High $0.65
- Year High $1.60
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $5.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.67
- Trailing P/E Ratio -1.51
- Forward P/E Ratio -1.51
- P/E Growth -1.51
- Net Income $-101,167,000
Income Statement
Quarterly
Annual
Latest News of XFOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Can a traffic-free Oxford Street match its global rivals?
London Mayor Sadiq Khan unveils a £150m plan to ban traffic on Oxford Street, aiming to revitalize it like Times Square or Champs-Élysées. Similar schemes in Paris, New York, and Barcelona have sho...
By The Guardian | 1 week ago -
Inside $178 billion Man Group's Oxford gathering: Academic hotshots, internal rising stars, and $25 trillion in institutional capital
Man Alternative Investment Symposium's 10th edition includes speakers, nature walks, and networking. Man Group president Steven Desmyter highlights the importance of deeper client relationships. The e...
By Business Insider | 2 weeks ago -
Oxford Industries, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oxford Industries missed analyst forecasts in its latest quarterly report, with revenues and earnings falling short. Analysts have adjusted their forecasts, expecting a revenue decline but a surge in ...
By Yahoo! Finance | 2 weeks ago
